Quality by Design as a risk-based strategy in pharmaceutical analysis: Development of a liquid chromatography-tandem mass spectrometry method for the determination of nintedanib and its impurities.
- DOI
- 10.1016/j.chroma.2019.460615
- Published
- 2020 Jan 25
- Container
- Journal of chromatography. A
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.chroma.2019.460615,
title = {Quality by Design as a risk-based strategy in pharmaceutical analysis: Development of a liquid chromatography-tandem mass spectrometry method for the determination of nintedanib and its impurities.},
author = {Pasquini B and Orlandini S and Furlanetto S and Gotti R and Del Bubba M and Boscaro F and Bertaccini B and Douša M and Pieraccini G},
year = {2020},
journal = {Journal of chromatography. A},
doi = {10.1016/j.chroma.2019.460615},
url = {https://doi.org/10.1016/j.chroma.2019.460615}
}RIS
TY - JOUR TI - Quality by Design as a risk-based strategy in pharmaceutical analysis: Development of a liquid chromatography-tandem mass spectrometry method for the determination of nintedanib and its impurities. AU - Pasquini B AU - Orlandini S AU - Furlanetto S AU - Gotti R AU - Del Bubba M AU - Boscaro F AU - Bertaccini B AU - Douša M AU - Pieraccini G PY - 2020 JO - Journal of chromatography. A DO - 10.1016/j.chroma.2019.460615 UR - https://doi.org/10.1016/j.chroma.2019.460615 ER -
APA
B, P., S, O., S, F., R, G., M, D. B., F, B., B, B., M, D., & G, P. (2020). Quality by Design as a risk-based strategy in pharmaceutical analysis: Development of a liquid chromatography-tandem mass spectrometry method for the determination of nintedanib and its impurities.. Journal of chromatography. A. https://doi.org/10.1016/j.chroma.2019.460615
Source records
- pubmed · retrieved 2026-09-25T23:41:20.481Z